Immune Therapeutics, Inc. Further Strengthens Balance Sheet as it Prepares for Commercialization
March 15, 2017 14:59 ET
|
Immune Therapeutics, Inc.
Highlights: Company Redeems Nearly All Outstanding Convertible DebenturesReplaces Nearly $650,000 of Long-Term Debt with Financing on Significantly Better Terms from a Strategic Long-Term...
IMMUNE THERAPEUTICS STRENGTHENS BALANCE SHEET; Reiterates Outlook for Positive Cash Flow by Mid Year
February 09, 2017 13:39 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and...
Immune Therapeutics Receives NAFDAC Approval for Lodonal(TM) in Nigeria: Approval Follows Successful Recent Bridging Study
April 27, 2016 10:19 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., April 27, 2016 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN) (the “Company”), a clinical-stage biotech company providing immunotherapy solutions for the treatment...